THALAMOSS
THALAssaemia MOdular Stratification System for personalized therapy of beta-thalassemia
| Coordinatore | UNIVERSITA DEGLI STUDI DI FERRARA
Organization address
address: SAVONAROLA 9 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 6˙681˙623 € |
| EC contributo | 5˙020˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-11-01 - 2016-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITA DEGLI STUDI DI FERRARA
Organization address
address: SAVONAROLA 9 contact info |
IT (FERRARA) | coordinator | 584˙000.00 |
| 2 |
IRBM SCIENCE PARK SPA
Organization address
address: VIA PONTINA KM 30600 contact info |
IT (POMEZIA RM) | participant | 600˙000.00 |
| 3 |
BIOCEPS
Organization address
address: "ZIV MEDICAL CENTER, THE RESEARCH DEPARTMENT, HARAMBAM STREET" contact info |
IL (TZFAT) | participant | 500˙000.00 |
| 4 |
THE CYPRUS FOUNDATION FOR MUSCULAR DYSTROPHY RESEARCH
Organization address
address: International Airport Avenue 6 contact info |
CY (AYIOS DOMETIOS) | participant | 440˙000.00 |
| 5 |
NOVAMECHANICS LIMITED
Organization address
address: JOHN KENNEDY AVENUE 62-64 contact info |
CY (LEFKOSIA) | participant | 406˙000.00 |
| 6 |
"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"
Organization address
address: Soranou Efesiou 4 contact info |
EL (ATHENS) | participant | 370˙000.00 |
| 7 |
CORNELL UNIVERSITY CORPORATION
Organization address
address: PINE TREE ROAD 373 contact info |
US (ITHACA NY) | participant | 370˙000.00 |
| 8 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 370˙000.00 |
| 9 |
GENIKO LAIKO NOSOKOMEIO ATHINON*GENERAL HOSPITAL OF ATHENS LAIKO
Organization address
address: AGIOU THOMA 17 contact info |
EL (ATHINA) | participant | 320˙000.00 |
| 10 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 320˙000.00 |
| 11 |
Masarykova univerzita
Organization address
address: Zerotinovo namesti 9 contact info |
CZ (BRNO STRED) | participant | 320˙000.00 |
| 12 |
UNIVERSITA DEGLI STUDI DI CAGLIARI
Organization address
address: VIA UNIVERSITA 40 contact info |
IT (CAGLIARI) | participant | 320˙000.00 |
| 13 |
HARBOUR ANTIBODIES BV
Organization address
address: DR. MOLEWATERPLEIN 50 KAM. EE 7-20 contact info |
NL (ROTTERDAM) | participant | 100˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'THALAMOSS is aimed at development of universal sets of markers and techniques for stratification of β-thalassaemia patients into treatment subgroups for (a) onset and frequency of blood transfusions, (b) choice of iron chelation, (c) induction of fetal hemoglobin, (d) prospective efficacy of gene-therapy. At present, no framework exists to guide therapeutic decisions and personalised treatment of β-thalassaemia. THALAMOSS Workpackages: WP1. Recruitment, patient characterization and development of erythroid precursor cells cultures; WP2. Omics analyses; WP3. Novel therapeutic approaches; WP4. Data analysis; WP5. Dissemination and exploitation; WP6. Regulatory and ethical issues; WP7. Management. The impact of THALAMOSS is the provision of novel biomarkers for distinct treatment subgroups in β-thalassaemia (500-1000 samples from four European medical centres), identified by combined genomics, proteomics, transcriptomics and tissue culture assays, and establishment of routine techniques for detection of these markers. Translation of these activities into the product portfolio and R&D methodology of participating SMEs will be a major issue. THALAMOSS tools and technologies will (a) facilitate identification of novel diagnostic tests, drugs and treatments specific to patient subgroups and (b) guide conventional and novel therapeutical approaches for β-thalassaemia, including personalised medical treatments. Key researchers of THALAMOSS are R.Gambari (Ferrara University, Italy), M. Kleanthous (The Cyprus Foundation for Muscular Dystrophy Research, Cyprus), S.Philipsen (Erasmus Universitair Medisch Centrum Rotterdam, The Netherlands), E.Katsantoni (Biomedical Research Foundation, Academy of Athens, Greece), S.Rivella (Weill Cornell Medical College, NY, USA), P.Holub (Masaryk University, Czech Republic), R.Galanello (Cagliari University, Italy), SL.Thein (King’s College Hospital, UK), E.Voskaridou (Laiko General Hospital, Greece). Participating SMEs are Biocep (Israel), NovaMechanics Ltd. (Cyprus) and IRBM (Italy). Industrial activities are also provided by Harbour Antibodies (The Netherlands).'
Introduzione (Teaser)
European researchers have joined forces to perform a multidisciplinary analysis of beta thalassaemia. Project deliverables will help stratify patients based on disease severity, and administer appropriate therapy.